{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:00Z","timestamp":1793068440394,"version":"4.5.0"},"reference-count":62,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Radioligand therapy (RLT) has reshaped the treatment landscape of advanced prostate cancer (PCa), offering a precision medicine approach that integrates molecular imaging with targeted radionuclide delivery, in which radioactive isotopes are bound to molecules that aim to selectively target cancer cells. The approval of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-prostate-specific membrane antigen (PSMA)-617 for metastatic castration-resistant prostate cancer marked a major milestone, with randomized trials (VISION, PSMAfore) demonstrating significant improvements in overall and progression-free survival compared to standard therapies. Beyond beta-emitting agents, next-generation alpha emitters such as actinium-225 and beta\/Auger electron-emitting isotopes like terbium\u2011161 are in active development, aiming to overcome resistance and target micrometastases with greater potency. Combination approaches, pairing RLT with poly(ADP-ribose) polymerase inhibitors, immune checkpoint blockade, or androgen receptor pathway inhibitors, for example, are under intense investigation, with early phase data indicating potential efficacy. Technical advances in imaging, personalized dosimetry, and molecular diagnostics may enable more precise patient selection and adaptive treatment strategies, such as dose adjustment based on dosimetry or target expression. Emerging RLT platforms target additional tumor markers, including human kallikrein 2 and six-transmembrane epithelial antigen of the prostate-2 as well as bispecific ligands, addressing disease heterogeneity and expanding therapeutic reach. Nonetheless, challenges remain around long-term hematologic and renal safety, radionuclide supply, protocol standardization, and global accessibility. Ongoing and future multicenter trials, collaborative consortia, and innovations in theranostics will be critical to defining optimal patient selection, sequencing with existing therapies, and embedding RLT as a key pillar in the management of advanced PCa.\n                  <\/jats:p>","DOI":"10.1177\/17588359251409047","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:36:09Z","timestamp":1768203369000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Current and future perspectives on radioligand therapy in advanced prostate cancer"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4351-9510","authenticated-orcid":false,"given":"Buraq","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"},{"name":"School of Clinical Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-4702","authenticated-orcid":false,"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.220200"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.01.010"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243295"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2139679"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4167-0"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.121"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2308"},{"key":"e_1_3_4_19_2","first-page":"43","article-title":"LuCarbo: a phase 1a\/1b trial of 177Lu-PSMA-617 (LuPSMA) with carboplatin in advanced prostate cancer","author":"Ravi P","year":"2025","unstructured":"Ravi P, Xie W, Paul M, et al. LuCarbo: a phase 1a\/1b trial of 177Lu-PSMA-617 (LuPSMA) with carboplatin in advanced prostate cancer. J Clin Oncol 2025; 43.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00573"},{"key":"e_1_3_4_21_2","unstructured":"Curium. Curium announces ECLIPSE trial has met primary endpoint demonstrating a statistically significant and clinically meaningful benefit for patients with PSMA-positive metastatic castration resistant prostate cancer https:\/\/www.curiumpharma.com\/2024\/11\/13\/eclipse-tiral-psma-prostate-cancer\/ (2024 accessed 22 July 2025)."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS256"},{"key":"e_1_3_4_23_2","unstructured":"Convergent Therapeutics. Convergent therapeutics announces two clinical trial updates on CONV01-\u03b1 at the American Society of Clinical Oncology (ASCO) genitourinary cancers symposium 2025 2025."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5005"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5017"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00451-5"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5016"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0451-z"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00135-9"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269252"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123133"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.796657"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00638-1"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT014"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04345-0"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00332-8"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267189"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050599"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1199432"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3746"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040779"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00030-5"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.07.009"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241298329"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.101"},{"issue":"7","key":"e_1_3_4_46_2","first-page":"1068","article-title":"177Lu-PSMA-617 consolidation therapy after docetaxel in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer: a randomized, phase 2 trial","volume":"66","author":"Satapathy S","year":"2025","unstructured":"Satapathy S, Das CK, Goyal S, et al. 177Lu-PSMA-617 consolidation therapy after docetaxel in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer: a randomized, phase 2 trial. J Nucl Med 2025; 66(7): 1068\u20131074.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5127"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.07.009"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.026"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07085-6"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00658-y"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2021.05.012"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00037-8"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.3645"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00407-8"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00891-1"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268640"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005251"},{"key":"e_1_3_4_60_2","article-title":"Clonal hematopoiesis in patients with neuroendocrine tumor treated with lutetium-177 and the risk of thrombocytopenia: a prospective study","volume":"8","author":"Kusne Y","year":"2024","unstructured":"Kusne Y, Lasho T, Finke C, et al. Clonal hematopoiesis in patients with neuroendocrine tumor treated with lutetium-177 and the risk of thrombocytopenia: a prospective study. JCO Precis Oncol 2024; 8: e2400143.","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5020"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3032"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265986"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251409047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251409047","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251409047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:59Z","timestamp":1777588439000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251409047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":62,"alternative-id":["10.1177\/17588359251409047"],"URL":"https:\/\/doi.org\/10.1177\/17588359251409047","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"17588359251409047"}}